Next-Generation Biomaterials for Wound Healing: Development and Evaluation of Collagen Scaffolds Functionalized with a Heparan Sulfate Mimic and Fibroblast Growth Factor 2
Source abstract
Abstract
Fibrosis after full-thickness wound healing—especially after severe burn wounds—remains a clinically relevant problem. Biomaterials that mimic the lost dermal extracellular matrix have shown promise but cannot completely prevent scar formation. We present a novel approach where porous type I collagen scaffolds were covalently functionalized with ReGeneRating Agent (RGTA®) OTR4120. RGTA® is a glycanase-resistant heparan sulfate mimetic that promotes regeneration when applied topically to chronic wounds. OTR4120 is able to capture fibroblast growth factor 2 (FGF-2), a heparan/heparin-binding growth factor that inhibits the activity of fibrosis-driving myofibroblasts. Scaffolds with various concentrations and distributions of OTR4120 were produced. When loaded with FGF-2, collagen–OTR4120 scaffolds demonstrated sustained release of FGF-2 compared to collagen–heparin scaffolds. Their anti-fibrotic potential was investigated in vitro by seeding primary human dermal fibroblasts on the scaffolds followed by stimulation with transforming growth factor β1 (TGF-β1) to induce myofibroblast differentiation. Collagen–OTR4120(-FGF-2) scaffolds diminished the gene expression levels of several myofibroblast markers. In absence of FGF-2 the collagen–OTR4120 scaffolds displayed an inherent anti-fibrotic effect, as the expression of two fibrotic markers (TGF-β1 and type I collagen) was diminished. This work highlights the potential of collagen–OTR4120 scaffolds as biomaterials to improve skin wound healing.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Wound Healing and Treatments · Tendon Structure and Treatment · Periodontal Regeneration and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medical BioSciences, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
Burn Research Lab, Alliance of Dutch Burn Care, 1941 AJ Beverwijk, The Netherlands
Department of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands
OTR3, 75001 Paris, France
Funding
Radboud University Medical Center
References (47)
Show source-provided references
1. Burn injury10.1038/s41572-020-0145-5 ↗
2. Schlottmann, F., Bucan, V., Vogt, P.M., and Krezdorn, N. (2021). A Short History of Skin Grafting in Burns: From the Gold Standard of Autologous Skin Grafting to the Possibilities of Allogeneic Skin Grafting with Immunomodulatory Approaches. Medicina, 57.10.3390/medicina57030225 ↗
3. Thin Split Thickness Skin Grafting on Human Acellular Dermal Matrix Scaffold for the Treatment of Deep Burn Wounds
4. Healing effect of acellular fish skin with plasma rich in growth factor on full-thickness skin defects10.1111/iwj.13821 ↗
5. Efficacy and Complications Associated with Acellular Dermal Substitute Use in the Treatment of Acute Burns: A Systematic Review and Meta-Analysis10.3390/ebj4040036 ↗
6. Fibroblast and myofibroblast activation in normal tissue repair and fibrosis10.1038/s41580-024-00716-0 ↗
7. Tai, Y., Woods, E.L., Dally, J., Kong, D., Steadman, R., Moseley, R., and Midgley, A.C. (2021). Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis. Biomolecules, 11.10.3390/biom11081095 ↗
8. Mechanical stretch sustains myofibroblast phenotype and function in microtissues through latent TGF-beta1 activation10.1093/intbio/zyaa015 ↗
9. Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro10.1038/s41374-017-0014-3 ↗
10. printing of growth factor-eluting adhesive scaffolds improves wound healing
11. Fabrication of SA/Gel/C scaffold with 3D bioprinting to generate micro-nano porosity structure for skin wound healing: A detailed animal in vivo study10.1186/s13619-022-00113-y ↗
12. Kim, J.H., Kim, T.H., Kang, M.S., and Kim, H.W. (2016). Angiogenic Effects of Collagen/Mesoporous Nanoparticle Composite Scaffold Delivering VEGF. Bio. Res. Int., 2016.10.1155/2016/9676934 ↗
13. Naomi, R., Ridzuan, P.M., and Bahari, H. (2021). Current Insights into Collagen Type, I. Polymers, 13.10.3390/polym13162642 ↗
14. Amirrah, I.N., Lokanathan, Y., Zulkiflee, I., Wee, M.F.M.R., Motta, A., and Fauzi, M.B. (2022). A Comprehensive Review on Collagen Type I Development of Biomaterials for Tissue Engineering: From Biosynthesis to Bioscaffold. Biomedicines, 10.10.3390/biomedicines10092307 ↗
15. Artificial dermal substitutes for tissue regeneration: Comparison of the clinical outcomes and histological findings of two templates10.1177/0300060520945508 ↗
16. Sarmin, A.M., El Moussaid, N., Suntornnond, R., Tyler, E.J., Kim, Y.H., Di Cio, S., Megone, W.V., Pearce, O., Gautrot, J.E., and Dawson, J. (2022). Multi-Scale Analysis of the Composition, Structure, and Function of Decellularized Extracellular Matrix for Human Skin and Wound Healing Models. Biomolecules, 12.10.3390/biom12060837 ↗
17. FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts10.1016/j.jdermsci.2017.08.013 ↗
18. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-410.1016/S0021-9258(20)80471-2 ↗
19. The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling10.1016/j.jtbi.2004.10.020 ↗
20. Heparin-conjugated collagen as a potent growth factor-localizing and stabilizing scaffold for regenerative medicine10.1016/j.reth.2020.10.002 ↗
21. Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats10.1002/jbm.10267 ↗
22. Interactions between extracellular matrix and growth factors in wound healing10.1111/j.1524-475X.2009.00466.x ↗
23. Olczyk, P., Mencner, L., and Komosinska-Vassev, K. (2015). Diverse Roles of Heparan Sulfate and Heparin in Wound Repair. Bio. Res. Int., 2015.10.1155/2015/549417 ↗
24. RGTA((R)) or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: From concept to curing patients10.1007/s10719-016-9744-5 ↗
25. Samakidou, G., Eleftheriadou, I., Anastasiou, I.A., Kosta, O., Tentolouris, A., Evangelou, K., and Tentolouris, N. (2024). A Single Center, Randomized Controlled Trial on the Efficacy of Topical Application of ReGenerating Tissue Agents (RGTA) Technology in Diabetic Foot Ulcers. Int. J. Low. Extrem. Wounds, 15347346241259893.10.1177/15347346241259893 ↗
26. (2006). Sterilization of Health Care Products—Radiation. Part 1: Requirements for Development, Validation and Routine Control of a Sterilization Process for Medical Devices (Standard No. ISO 11137-1:2006).
27. (2016). Medical Devices—Quality Management Systems—Requirements for Regulatory Purposes (Standard No. ISO 13485:2016).
28. A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine10.1038/s41420-020-00304-z ↗
29. 3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C310.1074/jbc.M506357200 ↗
30. Adaptive linear step-up procedures that control the false discovery rate10.1093/biomet/93.3.491 ↗
31. pH-responsive swelling behavior of collagen complex materials10.3109/10731190009119356 ↗
32. Fabrication of films with tailored properties by regulating the swelling of collagen fiber through pH adjustment10.1016/j.foodhyd.2020.106016 ↗
33. Heparin and heparan sulfate: Structure and function10.1039/b100916h ↗
34. Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides10.1016/j.biomaterials.2010.09.043 ↗
35. Relative retention of the fibroblast growth factors FGF-1 and FGF-2 on strong cation-exchange sorbents10.1016/j.chroma.2004.01.012 ↗
36. Growth factor delivery using extracellular matrix-mimicking substrates for musculoskeletal tissue engineering and repair
37. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific10.1074/jbc.272.29.18000 ↗
38. Rider, C.C., and Mulloy, B. (2017). Heparin, Heparan Sulphate and the TGF-beta Cytokine Superfamily. Molecules, 22.10.3390/molecules22050713 ↗
39. Ligand binding assays at equilibrium: Validation and interpretation10.1111/j.1476-5381.2009.00604.x ↗
40. Design, fabrication, and optimization of a dual function three-layer scaffold for controlled release of metformin hydrochloride to alleviate fibrosis and accelerate wound healing10.1016/j.actbio.2020.06.031 ↗
41. Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-beta110.1016/S0945-053X(01)00131-7 ↗
42. Urciuolo, F., Passariello, R., Imparato, G., Casale, C., and Netti, P.A. (2022). Bioengineered Wound Healing Skin Models: The Role of Immune Response and Endogenous ECM to Fully Replicate the Dynamic of Scar Tissue Formation In Vitro. Bioengineering, 9.10.3390/bioengineering9060233 ↗
43. Stimulation of toll-like receptor pathways by burn eschar tissue as a possible mechanism for hypertrophic scarring10.1111/wrr.12940 ↗
44. Experimental models and methods for cutaneous wound healing assessment10.1111/iep.12346 ↗
45. Hofmann, E., Schwarz, A., Fink, J., Kamolz, L.P., and Kotzbeck, P. (2023). Modelling the Complexity of Human Skin In Vitro. Biomedicines, 11.10.3390/biomedicines11030794 ↗
46. Key considerations on the development of biodegradable biomaterials for clinical translation of medical devices: With cartilage repair products as an example
47. TNF-alpha suppresses alpha-smooth muscle actin expression in human dermal fibroblasts: An implication for abnormal wound healing10.1038/sj.jid.5700890 ↗